0 339

Cited 0 times in

A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17)

DC FieldValueLanguage
dc.contributor.author김용배-
dc.contributor.author차지혜-
dc.date.accessioned2018-01-23T05:51:15Z-
dc.date.available2018-01-23T05:51:15Z-
dc.date.issued2015-
dc.identifier.issn0090-8258-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/155720-
dc.description.abstractOBJECTIVE: To investigate whether combined chemoradiotherapy (CTRT) confers a benefit for survival outcome over radiotherapy (RT) alone after primary surgery in patients with FIGO stage IIIC endometrial adenocarcinoma. METHODS: We conducted a multicenter retrospective study of patients with surgical stage IIIC endometrial cancer from 1990 to 2011. Adjuvant RT alone was performed in 85 patients (40.3%) and adjuvant CTRT in 126 patients (59.7%). Disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan-Meier method and Cox proportional hazards model. RESULTS: Stage IIIC1 and stage IIIC2 accounted for 63% and 37%, respectively. FIGO IIIC2 had a higher recurrence rate than FIGO IIIC1 (38.5% vs. 29.3%, p=0.172). Five-year OS and DFS were lower in FIGO IIIC2 than FIGO IIIC1 (85.1% vs. 76.9%, p=0.417; 71.0% vs. 59.2%, p=0.108, respectively). Eighteen patients (13.5%) in stage IIIC1 developed PALN recurrence, whereas only one (3.3%) in stage IIIC2 had PALN recurrence (p=0.001). In multivariate analysis, predictors of DFS were parametrial invasion (HR, 3.49; 95% CI, 1.83-6.64; p<0.001), higher grade (HR, 2.78; 95% CI, 1.31-5.89; p=0.008), and >3 positive pelvic nodes (HR, 1.84; 95% CI, 1.11-3.05; p=0.019). Combined CTRT did not affect DFS or OS in IIIC1 and IIIC2 compared with RT alone. CONCLUSION: CTRT showed comparable survival outcome to RT alone. Half of relapses (46%) in stage IIIC1 occurred in PALN region, whereas relapse in stage IIIC2 primarily occurred in distant metastasis (90%). Future randomized studies are needed to determine which subgroup may be most likely to benefit from CCRT.-
dc.description.statementOfResponsibilityrestriction-
dc.relation.isPartOfGYNECOLOGIC ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy*-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdenocarcinoma/radiotherapy*-
dc.subject.MESHAdenocarcinoma/surgery-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHChemoradiotherapy, Adjuvant-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEndometrial Neoplasms/drug therapy*-
dc.subject.MESHEndometrial Neoplasms/pathology-
dc.subject.MESHEndometrial Neoplasms/radiotherapy*-
dc.subject.MESHEndometrial Neoplasms/surgery-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRadiotherapy, Adjuvant-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHYoung Adult-
dc.titleA multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiation Oncology-
dc.contributor.googleauthorMee Sun Yoon-
dc.contributor.googleauthorWon Park-
dc.contributor.googleauthorSeung Jae Huh-
dc.contributor.googleauthorHak Jae Kim-
dc.contributor.googleauthorYoung Seok Kim-
dc.contributor.googleauthorYong Bae Kim-
dc.contributor.googleauthorJoo-Young Kim-
dc.contributor.googleauthorJong-Hoon Lee-
dc.contributor.googleauthorHun Jung Kim-
dc.contributor.googleauthorJihye Cha-
dc.contributor.googleauthorJin Hee Kim-
dc.contributor.googleauthorJuree Kim-
dc.contributor.googleauthorWon Sup Yoon-
dc.contributor.googleauthorJin Hwa Choi-
dc.contributor.googleauthorMison Chun-
dc.contributor.googleauthorYoungmin Choi-
dc.contributor.googleauthorSei Kyung Chang-
dc.contributor.googleauthorKang Kyoo Lee-
dc.contributor.googleauthorMyungsoo Kim-
dc.identifier.doi10.1016/j.ygyno.2015.06.030-
dc.contributor.localIdA00744-
dc.contributor.localIdA04009-
dc.relation.journalcodeJ00956-
dc.identifier.eissn1095-6859-
dc.identifier.pmid26115977-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0090825815300494-
dc.subject.keywordAdjuvant chemoradiotherapy-
dc.subject.keywordAdjuvant radiotherapy-
dc.subject.keywordEndometrial cancer-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.alternativeNameCha, Ji Hye-
dc.contributor.affiliatedAuthorKim, Yong Bae-
dc.contributor.affiliatedAuthorCha, Ji Hye-
dc.citation.volume138-
dc.citation.number3-
dc.citation.startPage519-
dc.citation.endPage525-
dc.identifier.bibliographicCitationGYNECOLOGIC ONCOLOGY, Vol.138(3) : 519-525, 2015-
dc.identifier.rimsid48179-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.